Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06270888 | Hypofractionation (Radiation) Trial for Multiple Myeloma | recruiting | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05674175 | Co-administration of CART22-65s and huCART19 for B-ALL | recruiting | Phase 1 / Phase 2 | 93 | Stephan Grupp MD PhDOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05702853 |
| Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL |
| recruiting |
| Phase 1 / Phase 2 |
| 27 |
| Medical University of South CarolinaOTHER |
| 1 |
| Mar 27, 2026 |
| clinicaltrials |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | recruiting | Phase 1 / Phase 2 | 606 | Sumitomo Pharma America, Inc.INDUSTRY | 12 | Mar 24, 2026 | clinicaltrials |
| NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 248 | Nurix Therapeutics, Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06153251 | A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 187 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT06207123 | A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) | recruiting | Phase 1 / Phase 2 | 15 | University of ChicagoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07477912 | Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma(MSTH-CAR001) | recruiting | Phase 1 / Phase 2 | 30 | Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06026319 | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | recruiting | Phase 1 | 24 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07473167 | Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients(TC011) | recruiting | Phase 1 / Phase 2 | 98 | TICAROS Co., Ltd.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06348108 | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 32 | Alfred Chung, MDOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06875063 | GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL | recruiting | Phase 1 | 45 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | recruiting | Phase 1 | 30 | Andrew E. Place, MDOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06623630 | Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function | recruiting | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05256641 | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07456371 | PIC1 Injection Therapy for Relapsed/Refractory B-NHL | recruiting | Phase 1 | 18 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05801913 | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07222631 | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas | recruiting | Phase 1 / Phase 2 | 48 | University of California, San DiegoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07294677 | CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL(CAVALRY) | recruiting | Phase 1 / Phase 2 | 104 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT01555892 | Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE(GRALE) | recruiting | Phase 1 | 136 | Baylor College of MedicineOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07169500 | Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05755087 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | Lapo AlinariOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06235229 | A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma(DURGA-3) | recruiting | Phase 1 / Phase 2 | 110 | Gracell Biotechnologies (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05432635 | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04421560 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | recruiting | Phase 1 / Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06475235 | Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL | recruiting | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04775745 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | recruiting | Phase 1 | 60 | Newave Pharmaceutical IncINDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT07333261 | Study of BMS-986453 in Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 | 25 | Susan BalOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07018752 | A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas(PlaTform) | recruiting | Phase 1 / Phase 2 | 49 | The Lymphoma Academic Research OrganisationOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04848064 | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | recruiting | Phase 1 | 12 | John ReneauOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03938987 | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)(ACIT001/EXC002) | recruiting | Phase 1 / Phase 2 | 63 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06574568 | A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 70 | Excyte Biopharma LtdINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05296304 | A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05892718 | A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors | recruiting | Phase 1 | 80 | FBD Biologics LimitedINDUSTRY | 3 | Feb 4, 2026 | clinicaltrials |
| NCT07114939 | FTT PET/CT in Pancreatic Neuroendocrine Tumors | recruiting | Phase 1 | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT04669171 | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma(SIDNEY) | recruiting | Phase 1 / Phase 2 | 80 | EnteromeINDUSTRY | 4 | Jan 30, 2026 | clinicaltrials |
| NCT06357676 | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial | recruiting | Phase 1 / Phase 2 | 27 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06829771 | Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07114367 | NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma(POTENTIAL-M) | recruiting | Phase 1 | 9 | NOBO MedicineINDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05371132 | Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) | recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06484985 | Study of AXT-1003 in Subjects With Advanced Malignant Tumors. | recruiting | Phase 1 | 78 | Axter Therapeutics (Beijing) Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07368270 | Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 30 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07369895 | Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 18 | O&D BioTech Group CO., LimitedINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06326463 | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | recruiting | Phase 1 | 18 | St. Jude Children's Research HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04855695 | Avo In R/R And Previously Untreated MCL | recruiting | Phase 1 / Phase 2 | 72 | Austin I KimOTHER | 1 | Jan 21, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 30, 2026source: clinicaltrials